Drugs / Human Lysozyme Goat Milk
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04177004 | Apr 2021 → Dec 2025 overdue | disease related to hematopoietic stem cell transplant, hematopoietic and lymphoid cell neoplasm | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03531281 | Dec 2018 → Dec 2022 | disease related to hematopoietic stem cell transplant, hematopoietic and lymphoid cell neoplasm | City of Hope Medical Center | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Lysozyme Goat Milk | “Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant” NCT04177004 ↗1“human lysozyme goat milk” NCT03531281 ↗ |
| Known as | hLZ | “human lysozyme goat milk (hLZ) treatment” NCT04177004 ↗ |
| Modality | Protein / enzyme biologic | “Human lysozyme is a natural enzyme found in human milk” NCT04177004 ↗ |
| Route | Oral | “human lysozyme goat milk orally (PO)” NCT04177004 ↗ |